CatSci Expands Global Presence
The company continues to expand globally through the completion of the Goldman Sachs 10,000 Small Businesses program and the hiring of Dr. Jas Douville, the company’s new head of business development for North America.
CatSci, a United Kingdom-based process research and development contract research organization, is continuing to expand globally through the recent completion of the Goldman Sachs 10,000 Small Businesses program and the hiring of Dr. Jas Douville, the company’s new head of business development for North America.
The company created Douville’s position to help deliver affordable, small-molecule therapeutics to meet the evolving healthcare needs of the world. Douville has experience working in R&D, direct sales, and business development for the global chemistry and pharma industries. The company announced his addition in a Sept. 3, 2019 press release.
“By becoming a member of the CatSci team, I am joining a group of highly skilled, dedicated, and like-minded people that aim to understand and solve difficult chemistry challenges,” said Douville in the press release. “Our common goal is allowing our customers to accelerate the development path from the lab through the clinic and all the way to commercial production for novel small-molecule therapeutics.”
CatSci CEO Dr. Ross Burn also expanded the company’s global presence by completing the 10,000 Small Businesses program funded by Goldman Sachs in partnership with the Said Business School at Oxford University, the Aston Centre for Growth at Aston University, Leeds University Business School, and Manchester Metropolitan University Business School, according to the press release. The program accelerates the business growth of organizations, helps create jobs and economic opportunities, and helped CatSci expedite its expansion process and create 25 jobs as part of a two-year business plan.
“We are delighted that CatSci is going from strength to strength in its strategic expansion plan,” said Ross in the press release. “It is fantastic to have Jas on board as we apply the knowledge gained through the 10,000 Small Business Program to increase our international presence in North America and beyond.”
Source: CatSci
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Ensuring Quality from the Start: Raw Materials Testing Support
November 21st 2024Raw Materials are the foundation of every biopharma product. Our ultimate guide highlights how our testing support can help you establish purity, identity, and quality standards, ensuring a smooth manufacturing process and adherence to regulatory requirements.
Ensure the Safety of Allogeneic Therapies with Advanced qPCR Testing
November 21st 2024Elevate your viral screening with Eurofins BioPharma Product Testing’s qPCR- based assays. Our advanced testing goes beyond standard screenings to detect even dormant and hard-to-detect pathogens, ensuring comprehensive safety in every stage of the allogeneic therapy pipeline. Protect your products – and your patients- with industry-leading sensitivity and specificity.
